Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
B-NHL 2013 for pediatric mature aggressive B-cell lymphoma and leukemia
2023-505509-18-00Phase 3Authorised
- Sponsor
- Universitätsklinikum Münster
- Start
- Jul 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 8
01
Overview
Phase 3, randomised, open-label trial of rituximab, doxorubicin, dexamethasone, methotrexate, cytarabine and 6 more in mature B-cell lymphoma, Burkitt lymphoma (BL), Burkitt leukemia and 1 more (4 arms), sponsored by Universitätsklinikum Münster. Primary endpoints: Event-free survival in R1/R2 stage I-II patients, Event-free survival in R2 stage III patients and 2 more. Planned start Jul 2017; status: authorised.
02
Drugs
rituximabdoxorubicindexamethasonemethotrexatecytarabine
03
Conditions
mature B-cell lymphomaBurkitt lymphoma (BL)Burkitt leukemiadiffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2023-505509-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505509-18-00.